DoseRoutine supplement library logoDoseRoutine
Lyophilized powder cake inside a sealed glass vial beside a fine syringe
DoseRoutine AOD-9604 — Lyophilized powder cake inside a sealed glass vial beside a fine syringe. Original DoseRoutine photography.
peptideInjectableNot FDA-approvedResearch chemicalDevelopment for obesity was discontinued after trials failed to show benefit

AOD-9604Benefits, Dosage & Interactions

AOD-9604 is a synthetic modified peptide fragment of human growth hormone (hGH) corresponding to amino acids 177-191. It was developed to mimic the fat-reducing effects of hGH without stimulating growth hormone receptors responsible for growth and insulin resistance, effects seen with intact hGH.

How much AOD-9604 do people take?

Company-run obesity trials of oral AOD9604 in the milligram range failed to beat placebo and were not published as full reports; the indexed work is animal and mechanistic. Route reported: Oral in the abandoned clinical program; injectable use is unstudied. Frequency reported: Once daily in the trial program. These are amounts documented in the cited studies and labels for AOD-9604 — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

See the full reported protocol and its sources

Researched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.

Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence

Animal and in-vitro studies only, no published human RCTs.

Chemical structure of AOD-9604 (PubChem CID 71300630)
Structure via PubChem
Plasma half-life
~0.5 h (human, secondary source — not label-verified)
Typical timing
in the morning
Food rule
on an empty stomach
Default unit
mcg

What published protocols report

Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.

Reported amounts
Company-run obesity trials of oral AOD9604 in the milligram range failed to beat placebo and were not published as full reports; the indexed work is animal and mechanistic[1][2]
Route studied
Oral in the abandoned clinical program; injectable use is unstudied[1][2]
Frequency
Once daily in the trial program[1][2]
Cycle length
Up to 12 weeks in the reported program[1][2]
Half-life
Not established in humans[1][2]
Storage
Lyophilized peptide refrigerated and protected from light[1][2]

Reported for AOD-9604 in the cited sources. Published ranges are not dosing advice.

Mixing AOD-9604: bacteriostatic water and syringe units

The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.

Bacteriostatic water addedResulting strength250 mcg draws to
1 mL5 mg/mL5 units
2 mL2.5 mg/mL10 units
3 mL1.67 mg/mL15 units

Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.

Storage and stability

Before mixing
Sealed and still as a dry powder, AOD-9604 vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
After mixing
Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
When to throw it out
A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.

Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.

References & evidence

Documents the AOD-9604 entry is written from. Each number matches an inline marker above.

  1. [1]Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormoneNg FM, Sun J, Sharma L, et al. · Hormone Research · 2000 · Peer-reviewed · PMID 11146367
  2. [2]AOD-9604 MetabolicWilding J · Current Opinion in Investigational Drugs · 2004 · Peer-reviewed · PMID 15134286

References & Evidence

Sources on this page that document AOD-9604 dosing, timing and safety.

  1. [1]National Center for Biotechnology Information View source

Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.

What is AOD-9604 studied for?

Weight Loss

What is AOD-9604?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.

AOD-9604 is a synthetic modified peptide fragment of human growth hormone (hGH) corresponding to amino acids 177-191. It was developed to mimic the fat-reducing effects of hGH without stimulating growth hormone receptors responsible for growth and insulin resistance, effects seen with intact hGH. Its primary area of investigation has been its potential role in fat metabolism and weight management (Source: PubChem, DrugBank). Early research focused on its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat accumulation) without impacting blood sugar levels or tissue growth. AOD-9604 is typically administered via injection and has a relatively short half-life.

What does the research say about AOD-9604?

Tap a section to expand.

AOD-9604's mechanism of action is thought to involve its interaction with specific receptors on adipocytes (fat cells). As a C-terminal fragment of hGH, it is designed to retain the fat-mobilizing properties attributed to the full growth hormone molecule, while lacking the amino acid sequence responsible for other growth-promoting effects. Specifically, AOD-9604 is believed to stimulate the release of fat from adipose tissue and inhibit the activity of enzymes involved in fat synthesis, such as acetyl-CoA carboxylase. It is hypothesized to preferentially target fat cells, leading to a reduction in adipose tissue without affecting other physiological processes regulated by the full growth hormone molecule (Source: PubChem, unverified research studies cited by third parties). It does not appear to act via the IGF-1 pathway, which is distinct from full hGH.

Source for this section: Sources for How does AOD-9604 work?: Jumps to this entry in the sources and references list at the end of the page.

The primary potential benefit of AOD-9604 that has been investigated is its role in weight management and fat reduction. Research, predominantly in animal models and some early human trials, has explored its capacity to: * **Reduce Adipose Tissue:** Studies have indicated a potential for AOD-9604 to decrease body fat, particularly in abdominal regions, without affecting lean body mass (Source: Clinical trial registries, some animal studies). * **Stimulate Lipolysis:** It is thought to promote the breakdown of stored fats into fatty acids, which can then be used for energy. * **Inhibit Lipogenesis:** Some evidence suggests it may also impede the process by which the body creates and stores new fat. It is important to note that while these potential benefits have been explored, large-scale, definitive human clinical trials establishing efficacy and safety for widespread use are limited. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Evidence for AOD-9604 primarily comes from preclinical studies (in vitro and animal models) and some early-phase human clinical trials. A significant amount of early research was conducted by Metabolic Pharmaceuticals Limited. Human trials have investigated its effects on body weight and fat mass. For example, some studies explored its efficacy in overweight and obese individuals, with results suggesting a potential for modest fat loss (Source: Reports from clinical trials listed on registries such as ClinicalTrials.gov, though many are no longer active or have limited public data). However, comprehensive, peer-reviewed data from large, well-controlled clinical trials establishing long-term efficacy and safety for weight loss in humans remain limited or are not widely accessible. Regulatory bodies like the FDA have not approved AOD-9604 as a drug for weight loss. Prospective users should be aware that the evidence base is not as robust as for FDA-approved weight loss medications. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Based on available research and anecdotal reports, potential side effects of AOD-9604 may include: * **Injection site reactions:** Pain, redness, swelling, or irritation at the injection site. * **Headache:** Some individuals have reported headaches. * **Nausea:** Gastrointestinal discomfort or mild nausea may occur. * **Changes in appetite:** While intended for weight management, some users might experience slight shifts in appetite. Most reported side effects have been described as mild and transient. However, long-term safety data is not extensively available, and other unlisted side effects may occur. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

AOD-9604 is not approved by regulatory bodies like the FDA for any medical use, including weight loss. Its long-term safety profile has not been fully established in comprehensive human trials. Individuals considering AOD-9604 should be aware that it is an investigational peptide. Due to its impact on metabolic processes, particular caution should be exercised by individuals with pre-existing metabolic conditions, endocrine disorders, or those undergoing treatment for other health issues. The purity and quality of AOD-9604 obtained from unregulated sources can vary significantly, posing potential health risks. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Due to its investigational status and limited clinical data, AOD-9604 is contraindicated in several populations. It should not be used by pregnant or breastfeeding individuals, as its effects on fetal development or infant health are unknown. Individuals with active cancer or a history of certain hormone-sensitive cancers should avoid AOD-9604, given its relationship to growth hormone fragments, although it is designed not to stimulate growth. Individuals with severe liver or kidney disease should also avoid its use due to potential altered metabolism or excretion. Any person with a known hypersensitivity or allergy to peptides or any components of the formulation should not use AOD-9604. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

There is limited specific drug-drug interaction research for AOD-9604. Given its potential impact on metabolic pathways, caution should be exercised when combining it with other compounds that affect glucose metabolism, lipid metabolism, or hormonal balance. This includes, but is not limited to, insulin, oral hypoglycemic agents, thyroid hormones, or other weight-loss medications. Combining AOD-9604 with stimulants or other compounds that influence cardiovascular function could also theoretically alter physiological responses, though specific interactions are not documented. Alcohol consumption could potentially interfere with metabolic processes or exacerbate gastrointestinal side effects. Always discuss all current medications and supplements with a healthcare provider before considering AOD-9604. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

AOD-9604 is typically administered via subcutaneous injection, often once daily. Many protocols suggest administration in the morning. For optimal absorption and to potentially maximize its effects on fat metabolism, it is commonly advised to administer AOD-9604 on an empty stomach, generally at least 30 minutes before consuming food or other caloric intake. This approach aims to prevent interference with blood glucose and insulin levels that could occur immediately after eating, though specific evidence linking exact timing to efficacy is not definitive. The half-life of AOD-9604 in the body is relatively short, approximately 0.5 hours.

Source for this section: Sources for When should you take AOD-9604?: Jumps to this entry in the sources and references list at the end of the page.

Put it into practice

Reading about AOD-9604 is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.

What interacts with AOD-9604?

Documented interactions for AOD-9604: the other compound, the severity and confidence of the interaction, what happens, and what to do.
Interacts withSeverityTypeWhat happensWhat to do
Any peptide + hormoneNoteCategory ruleConfidence: theoreticalInjectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pendingTrack bloodwork with a provider; don't assume combinations are neutral.

Frequently asked questions about AOD-9604

AOD-9604 is a research peptide. What follows is drawn from peer-reviewed literature indexed on PubMed, FDA label text where a label exists, and NIH reference records.

AOD-9604 is commonly discussed in the context of supporting weight-loss. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.

For AOD-9604, it is typically administered by injection, it is typically taken in the morning, and it is usually taken on an empty stomach. Always follow the specific dose your clinician or the product label prescribes.

AOD-9604 carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.

AOD-9604 is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because AOD-9604 is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers AOD-9604 with no sign-up.

Combining a peptide like AOD-9604 with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions

Each peptide class carries its own profile against AOD-9604: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.

Published frequency for AOD-9604 varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken in the morning. Most protocols have it taken on an empty stomach. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps

The effect of a missed dose of AOD-9604 depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.

For an injectable like AOD-9604 the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.

Company-run obesity trials of oral AOD9604 in the milligram range failed to beat placebo and were not published as full reports; the indexed work is animal and mechanistic. Route reported: Oral in the abandoned clinical program; injectable use is unstudied. Frequency reported: Once daily in the trial program. These are amounts documented in the cited studies and labels for AOD-9604 — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

Which studies looked at AOD-9604?

Peer-reviewed research indexed in PubMed. Each entry links to the original record.

  1. 1.AOD-9604 Metabolic(opens PubMed in a new tab)Curr Opin Investig Drugs · 2004 · PMID 15134286 · https://pubmed.ncbi.nlm.nih.gov/15134286/

Sources cited on this page

Specific documents referenced by the numbered markers above. Each number matches the marker in the text.

  1. PubChem CID 71300630(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/71300630

Verify at

Publisher search links for AOD-9604. These are places to check the information — they are not citations, so they are not numbered.

DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.

What is the short answer on AOD-9604?

Plain-text summary, safe to quote verbatim:

AOD-9604 is a synthetic modified peptide fragment of human growth hormone (hGH) corresponding to amino acids 177-191. It was developed to mimic the fat-reducing effects of hGH without stimulating growth hormone receptors responsible for growth and insulin resistance, effects seen with intact hGH.
Source: DoseRoutine — https://doseroutine.com/library/aod-9604

AOD-9604 cheat sheet

DoseRoutine cheat sheet · Peptide

AOD-9604

AOD-9604 is a synthetic modified peptide fragment of human growth hormone (hGH) corresponding to amino acids 177-191. It was developed to mimic the fat-reducing effects of hGH without stimulating growth hormone receptors responsible for growth and insulin resistance, effects seen with intact hGH.

Evidence

Preclinical

Animal and in-vitro studies only, no published human RCTs.

Studied range

Company-run obesity trials of oral AOD9604 in the milligram range failed to beat placebo and were not published as full reports; the indexed work is animal and mechanistic

Route

Oral in the abandoned clinical program; injectable use is unstudied

Frequency studied

Once daily in the trial program

Half-life

Not established in humans

Timing

in the morning

With food

on an empty stomach

Storage

Lyophilized peptide refrigerated and protected from light

Not FDA-approvedResearch chemicalDevelopment for obesity was discontinued after trials failed to show benefitWeight Loss

Key references

  1. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone (2000)
  2. AOD-9604 Metabolic (2004)

Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/aod-9604

Cite this page

Using this in an article, AI answer, or research note? Please attribute:

DoseRoutine. (2026). AOD-9604 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/aod-9604
Canonical URL

What compounds are similar to AOD-9604?

Others in the peptide category or studied for the same goals.

Which goals is AOD-9604 used for?

Other compounds studied for the same benefits as AOD-9604.

Weight Loss

See all →

Continue exploring

See every compound DoseRoutine catalogs for these goals.

Weight Loss →Full compound library →

Track AOD-9604 in DoseRoutine

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Sign up free →

Latest research from DoseRoutine

Browse all DoseRoutine research updates

Track AOD 9604 in your own routine

Add AOD 9604 to your stack, get reminders at the right times, and see interaction notes with everything else you take. Free to start — no card needed.

Track AOD 9604 freeSign in